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Background
Mutations in the GFPT1 and DPAGT1 genes, which
encode enzymes associated with roles in protein
N-linked glycosylation, have been recently identified in a
rare subgroup of patients with congenital myasthenic
syndromes (CMSs). These mutations are inherited in an
autosomal recessive pattern, and the mechanism of
impaired neuromuscular transmission may be acetylcho-
line receptor (AChR) deficiency due to impaired (AChR)
subunit glycosylation. Aberrant protein glycosylation is
also implicated in the development of severe cardiomyo-
pathies in the congenital disorders of glycosylation,
although the mechanisms responsible for cardiac invol-
vement are unknown. We investigated whether patients
with CMS and GFPT1 or DPAGT1 mutations also had
evidence of a cardiac phenotype.
Methods
We performed comprehensive cardiovascular magnetic
resonance (CMR) imaging at 1.5T (Avanto, Siemens),
31P spectroscopy at 3T (Tim Trio, Siemens) and echo-
cardiography to evaluate cardiac structure and function
in patients with GFPT1 (n = 2) and DPAGT1 (n = 2)
mutations. The mean age of the participants was 45
(range 25-57) and two were male.
Results
Electrocardiography was abnormal in all, with abnormal
repolarisation and deep S waves (n = 3) or marked left
ventricular hypertrophy by voltage criteria (n = 1).
Despite normal biventricular volumes and systolic func-
tion, GFPT1/DPAGT1 patients demonstrated late gado-
linium enhancement suggestive of myocardial fibrosis (n =
4, mean proportion of enhanced myocardium > 5 SD
above individual reference regions 3.2% +/-1.6, Figure 1),
impaired energetics (n = 2) and diastolic dysfunction
(n = 3). No patient had symptoms attributable to cardio-
vascular disease on structured interview.
Conclusions
Patients with GFPT1 or DPAGT1 mutations demonstrate
a cardiac phenotype including abnormal electrocardio-
graphy, myocardial fibrosis, diastolic dysfunction and
impaired energetics, despite normal systolic function.
These findings may reflect incipient cardiomyopathy due
to aberrant cardiac glycoprotein function. The reason for
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Figure 1 Representative electrocardiograph demonstrating
repolarization abnormalities with inversion of T-waves in
inferolateral leads and deep S waves.
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Table 1
Patient 1 Patient 2 Patient 3 Patient 4 Reference range
Age/years 57 58 38 25
Gender Female Female Male Male
Mutation DPAGT1 DPAGT1 GFPT1 GFPT1
















LVEDV/ml 104 142 124 144 102-218 ml (male)
83-187 (female
LVESV/ml 29 53 41 46 18-82 ml (male)
18-66 ml (female)
LVEF 72 63 67 68 57-81%
(male and female)
RVEF 75 64 66 70 47-71% (male)
53-73% (female)
LV mass/g 120 115 134 124 81-165 g (male)
42-150 g (female)
LGE regions Anterior septum and inferior LV/RV junction Basal inferolateral wall Basal inferolateral wall Inferior and inferolateral wall
LGE > 5SD/% 1.6 2.3 5.1 3.9
Stress perfusion CMR (visual assessment) Normal Not performed Normal Normal
PCr/ATP ratio 1.19 1.01 2.23 2.25
Diastolic function Grade 1 dysfunction Grade 2 dysfunction Grade 1 dysfunction Normal
Baseline characteristics and CMR and echo indices including left ventricular end diastolic volume (LVEDV), left ventricular end systolic volume (LVESV), left ventricular ejection fraction (LVEF), right ventricular ejection




















the milder phenotype than is seen many congenital disor-
ders of glycosylation may be greater residual enzyme
function as a consequence of a less pathogenic mutation.
This study highlights the utility of CMR for the assess-
ment of rare cardiac phenotypes and reinforces the need
for cardiac surveillance in patients with undefined or
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